XLO
Xilio Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.00
−0.22%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 64.1M | 43.8M | 6.3M | — | — |
| Cost of Revenue | 344.0K | 1.5M | — | — | — |
| Gross Profit | 63.7M | 42.2M | 6.3M | — | — |
| Operating Expenses | |||||
| R&D Expense | 66.8M | 56.0M | 41.2M | 52.1M | 59.2M |
| SG&A Expense | 28.3M | 29.7M | 24.8M | 27.0M | 29.9M |
| General & Admin Expense | 28.6M | 29.7M | 24.8M | 27.0M | 29.9M |
| Selling & Marketing Expense | (344.0K) | — | — | — | — |
| Other Expenses | — | (1.5M) | 937.0K | — | — |
| Total Operating Expenses | 95.1M | 84.2M | 66.9M | 79.1M | 89.1M |
| Cost and Expenses | 95.5M | 85.7M | 66.9M | 79.1M | 89.1M |
| Operating Income (EBIT) | (31.4M) | (42.0M) | (60.6M) | (79.1M) | (89.1M) |
| Non-Operating | |||||
| Interest Income | — | 3.4M | — | — | — |
| Interest Expense | — | — | 100.0K | — | — |
| Net Interest Income | — | 3.4M | (100.0K) | — | — |
| Other Non-Op Income/Expense | 9.5M | 6.9M | 2.3M | 2.7M | 927.0K |
| Non-Operating Income (excl Interest) | (9.5M) | (6.9M) | (937.0K) | (2.7M) | (927.0K) |
| EBT (Pre-Tax Income) | (21.8M) | (35.0M) | (58.2M) | (76.4M) | (88.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (21.8M) | (35.0M) | (58.2M) | (76.4M) | (88.2M) |
| Earnings from Cont. Ops | (21.8M) | (35.0M) | (58.2M) | (76.4M) | (88.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (21.8M) | (35.0M) | (58.2M) | (76.4M) | (88.2M) |
| Per Share | |||||
| Basic EPS | ($1.49) | ($4.19) | ($15.26) | ($38.92) | ($45.08) |
| Diluted EPS | ($1.64) | ($4.19) | ($15.26) | ($38.92) | ($45.08) |
| Revenue Per Share | $3.30 | $0.52 | $1.66 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 19.4M | 83.6M | 3.8M | 2.0M | 2.0M |
| Diluted Shares Outstanding | 19.4M | 83.6M | 3.8M | 2.0M | 2.0M |
| Profitability Metrics | |||||
| EBITDA | (20.5M) | (33.5M) | (58.0M) | (74.5M) | (86.4M) |
| D&A | 1.3M | 1.5M | 1.6M | 1.9M | 1.8M |
| EBIT | (21.8M) | (35.0M) | (59.6M) | (76.4M) | (88.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026